Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer

Abstract

S100A2, a calcium‐binding protein, recently became of major interest because of its differential expression during transformation and metastasis in various tumors. The purpose of this study was to investigate the prognostic significance of S100A2 expression in the early‐stage non small lung cancer (NSCLC). Immunohistochemical analysis to determine the percentage of cells staining positive for S100A2 was performed on 11 NSCLC tissue microarray slides containing samples from 113 patients with pathologic stage I NSCLC who had undergone curative surgery. S100A2 was expressed in samples from 79 patients (69.9%). Kaplan‐Meier analysis showed that patients whose tumors had positive S100A2 expression had a significantly lower overall survival and disease‐specific survival rate at 5 years after surgery than did patients with negative S100A2 expression (p < 0.001 and p < 0.001, respectively). Age at diagnosis, histologic type of cancer, degree of differentiation and smoking history did not have a statistically significant effect on survival. Multivariate analysis confirmed that S100A2 expression is a better predictor for disease‐specific survival than were other clinical and histologic variables tested. Our results suggested that the expression of the S100A2 protein in stage I NSCLC indicates poor prognosis and may be used to identify patients with early‐stage NSCLC who might benefit from adjuvant treatment. © 2005 Wiley‐Liss, Inc.

Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach

“…Positive Ki-67 expression was found to correlate with positive expression of both KCIP-1 (P ¼ 0.02) and EEF1A2 (P ¼ 0.01). To extend these findings, we then studied 11 tissue microarray blocks comprising normal and tumor tissue specimens from 113 patients with pathologic stage I non-small-cell lung cancer who had undergone curative surgery (Wang et al, 2005). Immunohistochemical analysis showed that EEF1A2 was expressed in 32 cases (28%) and KCIP-1 in 29 cases (26%).…”

“…Fluorescence in situ hybridization and immunohistochemical analyses of lung tissue microarrays Fluorescence in situ hybridizations and immunohistochemical analyses of KCIP-1 and EEF1A2 were carried out as described elsewhere (Jiang et al, 2002;Wang et al, 2005) with Lung Tissue Microarrays (Ambion, Austin, TX, USA) and 11 homemade microarray blocks containing tissue samples from 113 patients with pathologic stage I non-small-cell lung cancer (Wang et al, 2005). DNA probes specific for KCIP-1 and EEF1A2 were obtained by screening a Human BAC Clone library (Invitrogen) by polymerase chain reaction as described previously (Jiang et al, 2002).…”

The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC)

“…Early studies suggested that S100A2 expression is suppressed at an early stage of lung carcinogenesis [37], but later data indicated that it might be strongly expressed in the majority of NSCLC tumours [37,38]. In the most recent studies, it was proposed that over-expression of the S100A2 gene in stage I NSCLC indicates a poor prognosis, and may be used to identify patients with early-stage NSCLC [39], or even as a predictor of distant metastasis [40]. There could also be differences in the levels of expression according to the NSCLC type [38].…”

S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma

“…28 --31 Furthermore, overexpression of S100A2 was identified as a potential prognostic marker for poor disease-specific survival in patients with stage I NSCLC and pancreatic cancer. 9,11 Hypermethylation of the promoter region is a common mechanism of gene silencing. 32 --36 Site-specific DNA methylation of the S100A2 gene promoter in tumorigenic breast cancer cell lines has been shown to correlate with S100A2 repression during breast cancer progression.…”